Cost-savings to medicare from pre-medicare colorectal cancer screening
dc.contributor.author | Goede, S. | |
dc.contributor.author | Kuntz, K. | |
dc.contributor.author | Van Ballegooijen, M. | |
dc.contributor.author | Knudsen, A. | |
dc.contributor.author | Lansdorp_Vogelaar, Iris | |
dc.contributor.author | Tangka, F. | |
dc.contributor.author | Howard, D. | |
dc.contributor.author | Chin, J. | |
dc.contributor.author | Zauber, A. | |
dc.contributor.author | Seeff, L. | |
dc.date.accessioned | 2017-03-15T22:16:48Z | |
dc.date.available | 2017-03-15T22:16:48Z | |
dc.date.created | 2017-02-26T19:31:39Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Goede, S. and Kuntz, K. and Van Ballegooijen, M. and Knudsen, A. and Lansdorp_Vogelaar, I. and Tangka, F. and Howard, D. et al. 2015. Cost-savings to medicare from pre-medicare colorectal cancer screening. Medical Care. 53 (7): pp. 630-638. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/49924 | |
dc.identifier.doi | 10.1097/MLR.0000000000000380 | |
dc.description.abstract |
Background: Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Medicare populations (65+ y). Methods: We used 2 independently developed microsimulation models [Microsimulation Screening Analysis Colon (MISCAN) and Simulation Model of CRC (SimCRC)] to project CRC screening and treatment costs under 2 scenarios, starting in 2010: "current trends" (60% of the population up-to-date with screening recommendations) and "enhanced participation" (70% up-to-date). The population was scaled to the projected US population for each year between 2010 and 2060. Costs per year were derived by age group (50-64 and 65+ y). Results: By 2060, the discounted cumulative total costs in the pre-Medicare population were $35.7 and $28.1 billion higher with enhanced screening participation, than in the current trends scenario ($252.1 billion with MISCAN and $239.5 billion with SimCRC, respectively). Because of CRC treatment savings with enhanced participation, cumulative costs in the Medicare population were $18.3 and $32.7 billion lower (current trends: $423.5 billion with MISCAN and $372.8 billion with SimCRC). Over the 50-year time horizon an estimated 60% (MISCAN) and 89% (SimCRC) of the increased screening costs could be offset by savings in Medicare CRC treatment costs. Conclusion: Increased CRC screening participation in the pre-Medicare population could reduce CRC incidence and mortality, whereas the additional screening costs can be largely offset by long-term Medicare treatment savings. | |
dc.title | Cost-savings to medicare from pre-medicare colorectal cancer screening | |
dc.type | Journal Article | |
dcterms.source.volume | 53 | |
dcterms.source.number | 7 | |
dcterms.source.startPage | 630 | |
dcterms.source.endPage | 638 | |
dcterms.source.issn | 0025-7079 | |
dcterms.source.title | Medical Care | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |